超二倍体多发性骨髓瘤:染色体数目与细胞遗传学异常决定风险分层
该研究整合SNP-array与FISH分析694例新诊断中国多发性骨髓瘤(MM)患者,发现超二倍体(HRD)中染色体众数>49及3号染色体获得为稳健的有利预后标志,HRD仅对孤立1q21+患者带来生存获益,自体造血干细胞移植(AHSCT)的获益仅限于无高危细胞遗传学异常且染色体众数>49的低危HRD患者。
要点
- HRD患者中染色体众数>49预测更优OS(p=0.0062)和PFS(p=0.00037)。
- 3号染色体获得与更优OS(p=0.0024)和PFS(p=0.00078)相关。
- HRD仅改善孤立1q21+患者的OS(p=0.011),高危异常者无获益。
核心结论
- 染色体众数>49和3号染色体获得是HRD的稳健有利标志。
- HRD对孤立1q21+患者提供生存获益,但对高危细胞遗传学异常者无获益。
- AHSCT获益仅限于无高危异常且染色体众数>49的低危HRD患者。
研究设计与样本
- 整合SNP-array与FISH分析694例新诊断中国MM患者。
主要发现
- 染色体众数>49预测更优OS(p=0.0062)和PFS(p=0.00037),优于其他指标。
- 3号染色体获得与更优OS(p=0.0024)和PFS(p=0.00078)相关。
- HRD改善孤立1q21+患者OS(p=0.011),但对t(4;14)、t(14;16)、17p-或1p32-者无获益。
- 无高危异常且众数>49的HRD患者中,众数>49者OS更优(p=0.01)、PFS更优(p=0.001)。
- 孤立1q21+中众数>49显示有利趋势,其他高危异常中无区分度。
关键数值与推荐
- 染色体众数>49:OS p=0.0062,PFS p=0.00037。
- 3号染色体获得:OS p=0.0024,PFS p=0.00078。
- HRD对孤立1q21+的OS获益:p=0.011。
- AHSCT在低危高倍体HRD中OS获益:p=0.014,PFS趋势p=0.062。
临床怎么用
- FISH检测3号染色体三体可作为HRD风险分层的快速经济替代方法。
- 对HRD患者应结合染色体众数、3号染色体获得及高危细胞遗传学异常综合评估预后。
- AHSCT可考虑用于无高危异常且染色体众数>49的低危HRD患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hyperdiploidy (HRD) is the most common genetic subtype in multiple myeloma (MM) but with significant prognostic heterogeneity. In this integrated Single Nucleotide Polymorphism (SNP-array) and Fluorescence In Situ Hybridization (FISH) analysis of 694 newly diagnosed Chinese MM patients, a modal chromosome count >49 predicted superior overall survival (OS, p = 0.0062) and progression-free survival (PFS, p = 0.00037), outperforming other metrics. Gain of chromosome 3 was favourable for OS (p = 0.0024) and PFS (p = 0.00078). Notably, HRD improved OS in patients with isolated 1q21+ (p = 0.011) but not in those harbouring high-risk abnormalities (t(4;14), t(14;16), 17p- or 1p32-). The prognostic value of modal count was cytogenetic abnormality (CA)-dependent: in HRD without high-risk CAs, >49 conferred better OS (p = 0.01) and PFS (p = 0.001); in isolated 1q21+, a favourable trend was observed; but no discrimination in other high-risk CAs. Autologous haematopoietic stem cell transplantation (AHSCT) significantly improved OS (p = 0.014) and showed a PFS trend (p = 0.062) only in HRD patients without high-risk CAs and with >49 chromosomes. In conclusion, modal chromosome count >49 and chromosome 3 gain are robust favourable markers in HRD. HRD provides survival benefit in isolated 1q21+. FISH-based detection of trisomy 3 may offer a rapid, economical alternative for risk assessment of HRD. AHSCT benefit is restricted to low-risk HRD with higher ploidy.
引用
- Zeng Z, Lu J, Shang J, et al. Hyperdiploid multiple myeloma: A heterogeneous entity requiring refined risk stratification-Insights from chromosome count and cytogenetic abnormalities. Br J Haematol. 2026. PMID: 42760862. doi:10.1111/bjh.70817
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。